TRDX Trend Exploration Inc (PK)

SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. ("TRDX" or the "Company") (PINKSHEETS: TRDX) today announces to its shareholders that its negotiations are progressing well towards a definitive agreement with Genesis Biopharma, Inc. ("Genesis") to acquire an exclusive worldwide sublicense for a new compound in development for the treatment of Painful Diabetic Neuropathy (PDN).

The Company expects the definitive agreement and subsequent closing to be finalized in a reasonably short period of time.

Dr. Jan Stahl, CEO of TRDX, commented: "We are pleased to be nearing completion of negotiations with Genesis. Additionally, plans for funding the development of Genesis' PDN solution are progressing. We look forward to the successful completion of these key milestones in the near future."

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. (www.genesisbiopharma.com) is a Canadian corporation founded in 2007 to exploit the commercial potential for the therapeutic use of peptidomimetic (modified amino acid peptides) compounds. Amino acids are the building blocks of proteins, which are found in every cell of every living thing on Earth. Proteins consist of extremely long and complex amino acid chains. In contrast, a peptide is a short string of amino acids, joined by chemical bonds (also called "amide bonds").

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent (www.scimedenthealth.com) is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company's business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

Contact: SciMeDent Health Corp. f/k/a Trend Exploration, Inc. www.scimedenthealth.com dmyers@cadenceconsultingllc.com 1-866-383-1374